WEBULL
News
JAZZ
170.48
-0.19%
-0.32
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After a Strong Year-to-Date Share Price Rally
Simply Wall St · 5d ago
Weekly Report: what happened at JAZZ last week (1215-1219)?
Weekly Report · 5d ago
EXPLAINER-What will change if the US reclassifies marijuana?
Reuters · 12/17 23:22
Jazz Pharmaceuticals to Present Phase 3 Zanidatamab Trial Results at Investor Webcast
Reuters · 12/17 21:15
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
PR Newswire · 12/17 21:15
Weekly Report: what happened at JAZZ last week (1208-1212)?
Weekly Report · 12/15 09:52
Jazz Pharmaceuticals (JAZZ): Valuation Check After Positive Ziihera and Epidiolex Clinical Updates Boost Investor Interest
Simply Wall St · 12/14 23:22
Jazz Pharmaceuticals Completes Observational Study on Vyxeos Liposomal in AML Treatment
TipRanks · 12/14 16:34
How Fresh Epidiolex and Ziihera Data Accepted at Key Meetings At Jazz Pharmaceuticals (JAZZ) Has Changed Its Investment Story
Simply Wall St · 12/13 16:38
3 Value Stocks We’re Skeptical Of
Barchart · 12/12 03:52
Jazz Pharmaceuticals Exec Makes Significant Stock Sale
TipRanks · 12/12 02:09
Jazz Pharmaceuticals SVP Technical Operations Mary Elizabeth Henderson Reports Sale of Common Shares
Reuters · 12/11 22:20
Jazz Pharmaceuticals Files Initial Beneficial Ownership Statement for Director Ted W. Love
Reuters · 12/10 22:03
Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Raises Price Target to $219
Benzinga · 12/10 16:47
Jazz Pharmaceuticals price target raised to $219 from $147 at Piper Sandler
TipRanks · 12/10 11:35
Jazz Pharmaceuticals Executive Cashes In on Lucrative Stock Sale
TipRanks · 12/10 02:08
Jazz Pharmaceuticals SVP Chief Accounting Officer Patricia Carr Reports Disposal of Common Shares
Reuters · 12/09 22:25
Weekly Report: what happened at JAZZ last week (1201-1205)?
Weekly Report · 12/08 09:51
Do New Epidiolex Real‑World Data Reframe Jazz Pharmaceuticals' (JAZZ) Neurology Growth Ambitions?
Simply Wall St · 12/06 04:42
More
Webull provides a variety of real-time JAZZ stock news. You can receive the latest news about Jazz Pharmaceuticals Plc through multiple platforms. This information may help you make smarter investment decisions.
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.